Vantictumab, formerly labeled as OMP18R5, represents a novel monoclonal body designed with specifically target bone associated receptor 18R5. This treatment is being studied by researchers for anticipated applications https://ztndz.com/story28111400/vantictumab-the-deep-dive-into-the-engineered-immune-agent